Biogen Idec (BIIB +1.6%) says new data from Phase III studies evaluating its experimental...

Biogen Idec (BIIB +1.6%) says new data from Phase III studies evaluating its experimental multiple-sclerosis pill BG-12 showed strong clinical and positive radiological effects in people with relapsing-remitting MS. The data was presented at the 28th Congress of the European Committee for the Treatment and Research of Multiple Sclerosis in Lyon, France.

From other sites
Comments (2)
  • Shirley Kochman
    , contributor
    Comments (2) | Send Message
    Biogen has been one of my all time favorite stocks long before most people even knew that it existed. It was a small company before its merger, and I knew that it would be very successful because of the way the company was run and by whom it was run, and their great researchers. SEK,Dallas, Texas
    12 Oct 2012, 12:35 PM Reply Like
  • Shirley Kochman
    , contributor
    Comments (2) | Send Message
    I am a licensed counselor and a musician, a violinist and play in a symphony orchestra and in a smaller group that plays for parties and gives our money to Meals on Wheels and a scholarship fund.
    I always have been interested in medicine and research that could possibly help or cure various ills. That is when I became interested in Biogen in the early 1980s.
    Though I am not doing it much anymore, two of my musician partners and I had a successful cookie business and spent much of our earnings on buying stocks. That is when I learned about Biogen, when it was very young and inexpensive.
    12 Oct 2012, 01:36 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs